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Abstract
Meta-analysis has shown that successful Helicobacter pylori eradication therapy improved atrophic
gastritis and intestinal metaplasia. Moreover, successful eradication therapy against atrophic gastritis
has led to the suppression of the incidence of metachronous gastric cancer. Thus, the Japanese
Society for Helicobacter Research concluded that all ‘H. pylori-infected persons’ should be considered
for eradication therapy, irrespective of any background diseases. Successful eradication can prevent
transmission of this bacterium, and recent publications show that curing H. pylori infection seems to
reduce the risk of gastric cancer.
Introduction and context
Helicobacter pylori is a common worldwide infection and
is reported to cause various upper gastrointestinal tract
diseases, such as atrophic gastritis, gastroduodenal ulcer,
gastric cancer, gastric mucosa-associated lymphoid tissue
(MALT) lymphoma, and gastric hyperplastic polyp [1-3].
Although an infected person does not always develop
these severe outcomes, he or she has a high risk of
developing these diseases. Therefore, it is expected that
successful eradication therapy will result in the improve-
ment of histological gastritis and the prevention of
subsequent diseases. In particular, this may contribute to
the prevention of gastric cancer development, which is
one of the biggest medical problems in the world.
Various guidelines for the management of H. pylori
infection worldwide are available. For example, the
European Helicobacter Study Group published guide-
lines in the Maastricht III Consensus Report in 2005 [4]
and the American College of Gastroenterology (ACG)
issued guidelines in 2007 [5]. The Asia-Pacific Gastric
Cancer Consensus Conference was held in 2006, and the
consensus guidelines were also reported [6]. The current
consensus is that H. pylori screening and eradication
therapy are recommended for preventing the develop-
ment of gastric cancer. The latest guidelines were
reported from Japan in 2009 [7], and the most important
point in the guidelines was that all ‘H. pylori infection’
subjects were categorized as level A (i.e., there is strong
scientific evidence and eradication therapy is strongly
recommended).
Recent advances
The Japanese guidelines were revised dramatically in
January 2009, 6 years after the second revision [7]. In
particular, the results from the large-scale multicenter
trial in Japan published in 2008 helped the revision
greatly [8]. In that study, patients with early gastric cancer
who received endoscopic mucosal resection were ran-
domly divided into an eradication treatment group and a
non-eradication control group and the development of
metachronous gastric cancer was followed up for 3 years.
As a result, the treatment group had significantly lower
development of metachronous gastric cancer than the
non-eradication group. This study clearly showed that
the successful treatment of H. pylori infection led to a
decrease in the development of gastric cancer. This shows
that even in the background gastric mucosa of patients
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gastric cancer could be significantly suppressed by curing
the H. pylori infection, confirming the importance of
careful management of H. pylori-related gastritis.
It was recently reported from Taiwan that early eradica-
tion decreased the risk of gastric cancer in patients with
peptic ulcer disease [9]. In that study, 80,255 patients
hospitalized for peptic ulcer were evaluated for the
incidence of gastric cancer by a retrospective cohort
study. H. pylori infection was eradicated in a total of
54,576 patients within 1 year (median of 14 days) (early
eradication group) and in 25,679 patients after 1 year
(median of 1053 days) (late eradication group). On
examination by Kaplan-Meier, the cumulative incidence
of gastric cancer in the early eradication cohort was
significantly lower than the cumulative incidence in the
late eradication cohort. Using Cox multivariable propor-
tional hazard analysis, early H. pylori eradication was
found to be an independent protective factor for gastric
cancer development. These data suggest that early
eradication should be recommended for patients with
peptic ulcer to prevent the development of gastric cancer.
The latest meta-analysis confirmed that successful
eradication reduced the risk for gastric cancer [10]. The
authors searched the relevant medical publications in all
available sources, comparing H. pylori-positive patients
who had undergone eradication treatment with those
who had been untreated, and examined the number of
gastric cancer cases detected during the follow-up period.
Six randomized controlled trials met the criteria: four
from China, one from Japan, and one from Colombia.
The median follow-up period was 6 years. The pooled
analysis yielded a relative risk for gastric cancer of 0.65
(95% confidence interval [CI] 0.43-0.89) by undergoing
the successful eradication therapy (if data from two of
the reported trials from China are excluded, the relative
risk is 0.71, 95% CI 0.45-1.23). From a clinical point of
view, even a small reduction in risk and incidence
achieved with H. pylori eradication treatment would
probably give a huge advantage in terms of social health,
especially in high-risk areas.
Implications for clinical practice
These data confirmed that successful eradication was
effective for the prevention of not only peptic ulcer but
also gastric cancer. In the Maastricht III guidelines, peptic
ulcer, gastric MALT lymphoma, and patient wishes (after
full consultation with their physician) were all assigned a
grade A recommendation for H pylori eradication [4].
Established indications for treating H. pylori in the ACG
guidelines include peptic ulcer, gastric MALT lymphoma,
and uninvestigated dyspepsia. The Asia-Pacific Gastric
Cancer Consensus guidelines stated that H. pylori screen-
ing and treatment will reduce not only peptic ulcer and
dyspepsia symptoms but also the risk of developing
gastric cancer. As described above, the latest Japanese
guidelines state that all ‘H. pylori infection’ subjects should
be categorized as level A. However, an insurance system
(approval of health insurance coverage from the Japanese
government) was not taken into consideration in the
guidelines. Unfortunately, currently, peptic ulcer is the
only ‘approved’ indication for H. pylori eradication
therapy in Japan. Thus, the most H. pylori-infected
persons, except those with peptic ulcers, could not have
received the benefit of the eradication treatment. How-
ever, if all infected persons are to be treated, we should
consider the increase in frequency of antibiotic resistance
and unexpected consequences such as esophageal adeno-
carcinoma, asthma, and autoimmune disease [11].
It is clear that the countries with high incident rates
of gastric cancer have a high prevalence of H. pylori
infection. However, there are also populations, such as
those of India and Thailand, with a high prevalence of
H. pylori infection but purportedly low incidence rates of
gastric cancer. Infection with cytotoxin-associated gene
(cagA)-positive strains, especially East Asian cagA-posi-
tive strains, is believed to increase the risk for gastric
cancer over the risk associated with the cagA-negative
H. pylori infection [12]. Determining the cagA status in
H. pylori infection may confer additional benefit in
identifying populations at greater risk for gastric cancer.
However, the prevalence of the cagA gene in Asia is
extremely high, and currently identified cagA genotypes
in the Asia-Pacific region are not associated with gastric
cancer [6]. Interleukin-1 gene cluster polymorphisms are
associated with a higher risk of hydrochlorhydria and
gastric cancer in Western countries [13]; however, these
polymorphisms are not involved in the development of
gastric cancer in Asian countries [14]. These data suggest
that bacterial virulence factors, host genetic factors, and
environmental factors contribute to the risk for develop-
ing gastric cancer, and further studies investigating these
factors in concert are necessary to assess the effect of
H. pylori eradication on gastroduodenal pathogenesis.
Finally, it is important to recognize that the cure of
H. pylori infection in patients who have already devel-
oped advanced precancerous gastric lesions does not
completely prevent gastric cancer development [15]. The
Asia-Pacific Gastric Cancer Consensus guidelines con-
cluded that the optimal time to eradicate H. pylori is
before preneoplastic lesions (atrophy or intestinal
metaplasia) are present [4]. In high-risk populations
such as those of Japan and Korea, endoscopic surveil-
lance should continue to be performed.
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